MARKET

ALBO

ALBO

Albireo Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

38.90
-0.15
-0.38%
Closed 16:29 09/18 EDT
OPEN
39.05
PREV CLOSE
39.05
HIGH
39.58
LOW
38.55
VOLUME
333.00K
TURNOVER
--
52 WEEK HIGH
49.00
52 WEEK LOW
11.26
MARKET CAP
738.67M
P/E (TTM)
-6.5678
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
A Biotech Pro Bought Up These 3 Stocks
Barrons.com · 1d ago
Insider Buys Albireo Pharma's Shares
Perceptive Advisors Llc filed a Form 4 with the SEC on Tuesday, September 15. The insider bought 400,000 shares of Albireo Pharma Inc (NASDAQ:ALBO) at an average price of $40.00. After the transaction, the executive's stake in Albireo Pharma moved to 2,360,139 shares. Albireo Pharma was trading
Benzinga · 5d ago
Albireo raises $160M in public offering
Albireo Pharma (ALBO) has priced its public offering of 4M common shares at $40.00/share, for expected gross proceeds of $160M.Underwriters' over-allotment is an additional 600K shares.Closing date is September 14.Previously:
Seekingalpha · 09/10 03:44
Albireo Prices Public Offering of 4,000,000 Shares of Common Stock
BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common stock at
GlobeNewswire · 09/10 01:16
Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More
The biotech sector remains in focus with regulatory and other pipeline updates.
Zacks · 09/09 14:19
Company News for Sep 9, 2020
Companies in the news are: NKLA, BA, PTON, ALBO
Zacks · 09/09 14:08
The Daily Biotech Pulse: AstraZeneca Pauses Coronavirus Vaccine Study, Trillium To Get $25M Pfizer Investment
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) * Akouos Inc (NASDAQ: AKUS) * Albireo Pharma Inc (NASDAQ: ALB)(announced positive Phase 3 results for odevixibat in a liver disorder called progressive familial intrahepatic cholestasis) * Castle Biosciences Inc (NASDAQ: CSTL) * Harmony
Benzinga · 09/09 12:23
Albireo launches equity offering of 3M shares
Albireo Pharma (ALBO) has commenced a proposed underwritten public offering of 3M shares of its common stock, and underwriters have an option to purchase up to an additional 450k sharesPrice
Seekingalpha · 09/08 20:10
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALBO stock price target is 69.86 with a high estimate of 81.00 and a low estimate of 62.00.
EPS
Institutional Holdings
Institutions: 113
Institutional Holdings: 13.27M
% Owned: 69.87%
Shares Outstanding: 18.99M
TypeInstitutionsShares
Increased
33
417.27K
New
22
185.53K
Decreased
19
777.14K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
Chairman/Independent Director
David Chiswell
President/Chief Executive Officer/Director
Ronald Cooper
Chief Financial Officer/Treasurer
Simon Harford
Chief Human Resource Officer
Michelle Graham
Chief Scientific Officer
Jan Mattsson
General Counsel/Secretary
Jason Duncan
Other
Martha Carter
Other
Patrick Horn
Other
Pamela Stephenson
Independent Director
Michael Gutch
Independent Director
Roger Jeffs
Independent Director
Anne Klibanski
Independent Director
Stephanie Okey
Independent Director
Davey Scoon
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average ALBO stock price target is 69.86 with a high estimate of 81.00 and a low estimate of 62.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALBO
Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Albireo Pharma Inc stock information, including NASDAQ:ALBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALBO stock methods without spending real money on the virtual paper trading platform.